Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triamcinolone acetonide + dexamethasone + bupivacaine
- Development stage
- Unknown
- Lead developer
- University of North Carolina at Chapel Hill
- Modality
- Small Molecules
- Administration
- Intraarticular
01
Overview
This therapeutic combination consists of two corticosteroids, triamcinolone acetonide and dexamethasone, and the local anesthetic bupivacaine. It was studied by the University of North Carolina, Chapel Hill, as a comparator to platelet-rich plasma (PRP) for the treatment of partial thickness rotator cuff tears. Triamcinolone acetonide is a synthetic glucocorticoid used for its intermediate-acting anti-inflammatory effects, while dexamethasone provides potent, long-acting corticosteroid activity. Bupivacaine is included to provide immediate regional anesthesia. The combination is administered via ultrasound-guided injection into the glenohumeral joint to alleviate pain and reduce inflammation associated with tendon injury.
- Brand names
- Kenalog
- Other names
- triamcinolone acetonide + dexamethasone + bupivacaineCorticosteroid injection (UNC)
02
Targets
GR (Glucocorticoid receptor)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on triamcinolone acetonide + dexamethasone + bupivacaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triamcinolone acetonide + dexamethasone + bupivacaine.